233 related articles for article (PubMed ID: 18336216)
1. High throughput screening for neurodegeneration and complex disease phenotypes.
Varma H; Lo DC; Stockwell BR
Comb Chem High Throughput Screen; 2008 Mar; 11(3):238-48. PubMed ID: 18336216
[TBL] [Abstract][Full Text] [Related]
2. Drug screening for Huntington's disease and other neurodegenerative disorders.
Varma H
Curr Mol Pharmacol; 2010 Nov; 3(3):164-73. PubMed ID: 20858196
[TBL] [Abstract][Full Text] [Related]
3. Small molecule drug discovery for Huntington's Disease.
Fecke W; Gianfriddo M; Gaviraghi G; Terstappen GC; Heitz F
Drug Discov Today; 2009 May; 14(9-10):453-64. PubMed ID: 19429504
[TBL] [Abstract][Full Text] [Related]
4. Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases.
Krainc D
Arch Neurol; 2010 Apr; 67(4):388-92. PubMed ID: 20385902
[TBL] [Abstract][Full Text] [Related]
5. Biologically active molecules that reduce polyglutamine aggregation and toxicity.
Desai UA; Pallos J; Ma AA; Stockwell BR; Thompson LM; Marsh JL; Diamond MI
Hum Mol Genet; 2006 Jul; 15(13):2114-24. PubMed ID: 16720620
[TBL] [Abstract][Full Text] [Related]
6. High throughput screening technology and the small molecules modulating aging related signals.
Mo C; Zhang W; Liu L; Wang L; Xiao H
Comb Chem High Throughput Screen; 2012 Mar; 15(3):242-52. PubMed ID: 22221057
[TBL] [Abstract][Full Text] [Related]
7. Cell death assays for neurodegenerative disease drug discovery.
Linsley JW; Reisine T; Finkbeiner S
Expert Opin Drug Discov; 2019 Sep; 14(9):901-913. PubMed ID: 31179783
[No Abstract] [Full Text] [Related]
8. Therapeutic approaches to preventing cell death in Huntington disease.
Kaplan A; Stockwell BR
Prog Neurobiol; 2012 Dec; 99(3):262-80. PubMed ID: 22967354
[TBL] [Abstract][Full Text] [Related]
9. A phenotypic screening assay for modulators of huntingtin-induced transcriptional dysregulation.
Lazzeroni G; Benicchi T; Heitz F; Magnoni L; Diamanti D; Rossini L; Massai L; Federico C; Fecke W; Caricasole A; La Rosa S; Porcari V
J Biomol Screen; 2013 Oct; 18(9):984-96. PubMed ID: 23562876
[TBL] [Abstract][Full Text] [Related]
10. High-throughput screening in primary neurons.
Sharma P; Ando DM; Daub A; Kaye JA; Finkbeiner S
Methods Enzymol; 2012; 506():331-60. PubMed ID: 22341232
[TBL] [Abstract][Full Text] [Related]
11. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
Chopra V; Fox JH; Lieberman G; Dorsey K; Matson W; Waldmeier P; Housman DE; Kazantsev A; Young AB; Hersch S
Proc Natl Acad Sci U S A; 2007 Oct; 104(42):16685-9. PubMed ID: 17925440
[TBL] [Abstract][Full Text] [Related]
12. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases.
Outeiro TF; Giorgini F
Biotechnol J; 2006 Mar; 1(3):258-69. PubMed ID: 16897706
[TBL] [Abstract][Full Text] [Related]
13. High content screening in neurodegenerative diseases.
Jain S; van Kesteren RE; Heutink P
J Vis Exp; 2012 Jan; (59):e3452. PubMed ID: 22257990
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial permeability transition pore: a potential drug target for neurodegeneration.
Kalani K; Yan SF; Yan SS
Drug Discov Today; 2018 Dec; 23(12):1983-1989. PubMed ID: 30081095
[TBL] [Abstract][Full Text] [Related]
15. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity.
Boyd JD; Lee P; Feiler MS; Zauur N; Liu M; Concannon J; Ebata A; Wolozin B; Glicksman MA
J Biomol Screen; 2014 Jan; 19(1):44-56. PubMed ID: 24019256
[TBL] [Abstract][Full Text] [Related]
16. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
Sontag EM; Lotz GP; Agrawal N; Tran A; Aron R; Yang G; Necula M; Lau A; Finkbeiner S; Glabe C; Marsh JL; Muchowski PJ; Thompson LM
J Neurosci; 2012 Aug; 32(32):11109-19. PubMed ID: 22875942
[TBL] [Abstract][Full Text] [Related]
17. AlphaScreen-Based Assays: Ultra-High-Throughput Screening for Small-Molecule Inhibitors of Challenging Enzymes and Protein-Protein Interactions.
Yasgar A; Jadhav A; Simeonov A; Coussens NP
Methods Mol Biol; 2016; 1439():77-98. PubMed ID: 27316989
[TBL] [Abstract][Full Text] [Related]
18. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins.
Butterfield DA; Kanski J
Mech Ageing Dev; 2001 Jul; 122(9):945-62. PubMed ID: 11348660
[TBL] [Abstract][Full Text] [Related]
19. From target identification to drug screening assays for neurodegenerative diseases.
Zuccato C; Tartari M; Goffredo D; Cattaneo E; Rigamonti D
Pharmacol Res; 2005 Sep; 52(3):245-51. PubMed ID: 15916902
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
